AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33579762 — intervention group
Group type: EXPERIMENTAL
Intervention: HOLOBalance
Number of subjects: 120
Study 33579762 — intervention group
Group type: COMPARATOR
Intervention: OTAGO Home Exercise Programme
Number of subjects: 120
Study 36259401 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning session
Number of subjects: 0
Study 36259401 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 0
Study 36259401 — intervention group
Group type: COMPARATOR
Intervention: Workshop instruction activity
Number of subjects: 0
Study 34191352 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg/d
Number of subjects: 66
Study 34191352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 34191352 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 75 mg/d, 150 mg/d, 300 mg/d
Number of subjects: 66
Study 36084494 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 37.5 mg/d
Number of subjects: 0
Study 36084494 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 75 mg/d
Number of subjects: 0
Study 36084494 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg/d
Number of subjects: 0
Study 36084494 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg/d
Number of subjects: 0
Study 36084494 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol (all doses combined)
Number of subjects: 0
Study 36084494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33318635 — intervention group
Group type: EXPERIMENTAL
Intervention: AV-101 (1440 mg)
Number of subjects: 10
Study 33318635 — intervention group
Group type: EXPERIMENTAL
Intervention: AV-101 (720 mg)
Number of subjects: 10
Study 33318635 — intervention group
Group type: EXPERIMENTAL
Intervention: AV-101 (720 mg and 1440 mg)
Number of subjects: 10
Study 33318635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 36461655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian-guided AUC0-24h/MIC
Number of subjects: 45
Study 36461655 — intervention group
Group type: COMPARATOR
Intervention: Trough level monitoring
Number of subjects: 45
Study 32260047 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine-assisted intervention (riding once a week, led by a certified therapist)
Number of subjects: 14
Study 32260047 — intervention group
Group type: COMPARATOR
Intervention: Control group Passive (lacked regular activities outside the home)
Number of subjects: 14
Study 32260047 — intervention group
Group type: COMPARATOR
Intervention: Control group Active (had several activities outside the home per week)
Number of subjects: 14
Study 34271944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with weight loss
Number of subjects: 185
Study 34271944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet without weight loss
Number of subjects: 185
Study 34271944 — intervention group
Group type: COMPARATOR
Intervention: Control group (face to face)
Number of subjects: 185
Study 34271944 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote data collection (group 3)
Number of subjects: 185
Study 35358462 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 35358462 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of next-generation hormonal drug
Number of subjects: 0
Study 34421801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and endurance training (EXP)
Number of subjects: 27
Study 34421801 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 27
Study 32581112 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic hazard score (PHS) informed screening
Number of subjects: 0
Study 32581112 — intervention group
Group type: COMPARATOR
Intervention: PSA testing
Number of subjects: 0
Study 32919388 — intervention group
Group type: EXPERIMENTAL
Intervention: XtraMath® (math training)
Number of subjects: 65
Study 32919388 — intervention group
Group type: COMPARATOR
Intervention: Cogmed® (active control condition; working memory)
Number of subjects: 65
Study 32919388 — intervention group
Group type: EXPERIMENTAL
Intervention: XtraMath®
Number of subjects: 65
Study 32487213 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative placebo therapy (ceftriaxone 2 g/24 h and metronidazole 1500 mg/24 h for 3 days)
Number of subjects: 1494
Study 32487213 — intervention group
Group type: COMPARATOR
Intervention: Post-operative antibiotic therapy (ceftriaxone 2 g/24 h and metronidazole 1500 mg/24 h for 3 days)
Number of subjects: 1494
Study 34405414 — intervention group
Group type: EXPERIMENTAL
Intervention: Design-thinking based education program
Number of subjects: 105
Study 34004339 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up publications with different primary outcomes compared to original RCTs
Number of subjects: 78
Study 34004339 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up publications with outcome switches not pre-specified or explained
Number of subjects: 78
Study 34004339 — intervention group
Group type: COMPARATOR
Intervention: Initial RCTs with outcome switching
Number of subjects: 78
Study 32438531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) with 100% or 70% of calculated weekly energy requirements for 8 weeks
Number of subjects: 0
Study 36195542 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen, 300 mg weekly for 16 weeks
Number of subjects: 5
Study 36195542 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen, 300 mg weekly for 32-52 weeks
Number of subjects: 5
Study 36195542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 33752216 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate memory in men
Number of subjects: 492
Study 33752216 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural sway in women
Number of subjects: 492
Study 33752216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand reaction time in women
Number of subjects: 492
Study 33752216 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC of gait speed, cadence, and double support time in women
Number of subjects: 492
Study 33752216 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC of gait speed, step length, and double support time in men
Number of subjects: 492
Study 33143484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and evening primrose oil co-supplementation
Number of subjects: 0
Study 33143484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34837510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 131I-mIBG therapy (666 MBq/kg)
Number of subjects: 8
Study 34837510 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose chemotherapy (HDC)
Number of subjects: 8
Study 34837510 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematopoietic stem cell transplantation (HSCT)
Number of subjects: 8
Study 34837510 — intervention group
Group type: EXPERIMENTAL
Intervention: Response according to RECIST 1.1
Number of subjects: 8
Study 34837510 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphic response
Number of subjects: 8
Study 32675541 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective Sigmoid Resection within 6 weeks
Number of subjects: 0
Study 32675541 — intervention group
Group type: COMPARATOR
Intervention: Conservative Management
Number of subjects: 0
Study 36336337 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training with an avatar in VR
Number of subjects: 30
Study 36336337 — intervention group
Group type: COMPARATOR
Intervention: VR without an avatar (Control)
Number of subjects: 30
Study 32578488 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsifen (200 mg × 1/day, 4 mg capsaicinoids/day)
Number of subjects: 24
Study 32578488 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsifen
Number of subjects: 24
Study 32578488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32860783 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL) group
Number of subjects: 122
Study 32860783 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods group
Number of subjects: 122
Study 34176370 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) with blue-light-reducing features activated
Number of subjects: 55
Study 34176370 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG) with no blue-light-reducing features
Number of subjects: 55
Study 34972765 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BZN) and Nifurtimox (NFX) chemotherapy regimens
Number of subjects: 450
Study 34972765 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) BZN and NFX
Number of subjects: 450
Study 34602021 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk and lower extremity long-axis rotation exercise (20-minute sessions)
Number of subjects: 36
Study 34964849 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 1279
Study 34964849 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1279
Study 33966880 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive training (90% positive-10% negative)
Number of subjects: 807
Study 33966880 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% positive-50% negative training
Number of subjects: 807
Study 33966880 — intervention group
Group type: COMPARATOR
Intervention: No-training control
Number of subjects: 807
Study 33966880 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious imagery prime
Number of subjects: 807
Study 33966880 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral imagery prime
Number of subjects: 807
Study 32345375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program consisting of detecting symptoms of mental illness, strengthening parenting skills using the Circle of Security Parenting program, supporting breastfeeding, and organizing treatment pathways.
Number of subjects: 76
Study 32345375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 76
Study 32345375 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 76
Study 35575051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional-dose IPV (fIPV, one-fifth of IPV) - 1 dose
Number of subjects: 0
Study 35575051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional-dose IPV (fIPV, one-fifth of IPV) - 2 doses
Number of subjects: 0
Study 35575051 — intervention group
Group type: COMPARATOR
Intervention: Full-dose IPV
Number of subjects: 0
Study 35575051 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose IPV - 2 doses
Number of subjects: 0
Study 33609248 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 (liposomal daunorubicin and cytarabine)
Number of subjects: 0
Study 33609248 — intervention group
Group type: COMPARATOR
Intervention: Standard therapeutic options
Number of subjects: 0
Study 33609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with azacitidine
Number of subjects: 0
Study 33609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials with low- and high-intensity therapies
Number of subjects: 0
Study 32448020 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole (50 mg)
Number of subjects: 37
Study 32448020 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 36175104 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patient education comprising of a video and prehabilitation programme with standard care
Number of subjects: 100
Study 36175104 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 33440997 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic susceptibility to smoking (measured by a polygenic risk score)
Number of subjects: 408609
Study 33355781 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated System (ultrasound-guided and electrocardiogram confirmation)
Number of subjects: 165
Study 33355781 — intervention group
Group type: COMPARATOR
Intervention: Anthropometric estimation of device length (Control)
Number of subjects: 165
Study 35997845 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships® (PFR)
Number of subjects: 162
Study 33960689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 13
Study 32777737 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus 6 months Mycophenolate mofetil (MMF)
Number of subjects: 122
Study 32777737 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 6 months Mycophenolate mofetil (MMF)
Number of subjects: 122
Study 34800079 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (titrated up to a maximum of three packs/day, 8.4 g/pack)
Number of subjects: 820
Study 34800079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (patiromer withdrawal)
Number of subjects: 820
Study 34800079 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 820
Study 34563120 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) exercises based on Xbox Kinect, 2 sessions of 30-45 minutes weekly for 6 weeks
Number of subjects: 60
Study 34563120 — intervention group
Group type: COMPARATOR
Intervention: Routine exercises of the nursing homes (Control)
Number of subjects: 60
Study 36044317 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Aviptadil for 3 days
Number of subjects: 196
Study 36044317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 34597975 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib alone
Number of subjects: 602
Study 34597975 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 602
Study 34597975 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bevacizumab
Number of subjects: 602
Study 32790066 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg glasdegib
Number of subjects: 36
Study 32790066 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg glasdegib
Number of subjects: 36
Study 32790066 — intervention group
Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 36
Study 32790066 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 32199696 — intervention group
Group type: EXPERIMENTAL
Intervention: IF 5:2 diet
Number of subjects: 38
Study 35753072 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) four times weekly (EX; n=20)
Number of subjects: 30
Study 35753072 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON; n=10)
Number of subjects: 30
Study 33765717 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 282
Study 33765717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 282
Study 35794462 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer learning intervention (HBB and ECEB training, 1 day peer learning course, peer practice scenarios, mentorship visits at 2 to 3 and 6 to 7 months)
Number of subjects: 36
Study 35794462 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer learning intervention
Number of subjects: 36
Study 35794462 — intervention group
Group type: COMPARATOR
Intervention: Control (HBB and ECEB training alone)
Number of subjects: 36
Study 35794462 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 34511098 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride toothpaste (Test)
Number of subjects: 130
Study 34511098 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate toothpaste (Control)
Number of subjects: 130
Study 32613649 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 250
Study 32613649 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 250
Study 35427629 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPAD
Number of subjects: 137
Study 35427629 — intervention group
Group type: COMPARATOR
Intervention: No RADPAD
Number of subjects: 137
Study 34118716 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 373
Study 34118716 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (BUP-NX)
Number of subjects: 373
Study 33066859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 62
Study 33066859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 35534883 — intervention group
Group type: EXPERIMENTAL
Intervention: Longmu Tang granule
Number of subjects: 60
Study 35534883 — intervention group
Group type: COMPARATOR
Intervention: Placebo granule
Number of subjects: 60
Study 32947383 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine 10% plus levofloxacin 0.5% at 1 hour preoperatively
Number of subjects: 142
Study 32947383 — intervention group
Group type: COMPARATOR
Intervention: Control group (received PVI just before the operation)
Number of subjects: 142
Study 35485424 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 709
Study 35485424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study 35112661 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT)
Number of subjects: 7
Study 35112661 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control session (CTL)
Number of subjects: 7
Study 33637837 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive algorithm guided treatment
Number of subjects: 913
Study 33637837 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TaU)
Number of subjects: 913
Study 32162501 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 44
Study 32162501 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 44
Study 32162501 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance training (SE)
Number of subjects: 44
Study 32162501 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 44
Study 35510542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study 34616464 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg) for two weeks at 10 PM
Number of subjects: 0
Study 34616464 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two weeks at 10 PM
Number of subjects: 0
Study 34616464 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 0
Study 34666693 — intervention group
Group type: EXPERIMENTAL
Intervention: UV irradiation (half-body UV irradiation, twice weekly over 6 months at one standard erythema dose)
Number of subjects: 61
Study 34666693 — intervention group
Group type: EXPERIMENTAL
Intervention: UV irradiation
Number of subjects: 61
Study 34666693 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation (5600 international units of cholecalciferol once a week)
Number of subjects: 61
Study 34666693 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 61
Study 32913645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive Eating (IE)
Number of subjects: 56
Study 32913645 — intervention group
Group type: COMPARATOR
Intervention: Pinned Eating (PE)
Number of subjects: 56
Study 33546739 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg once daily, can be reduced to 2 mg) for 5-7 days
Number of subjects: 136
Study 33546739 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (including antibiotics, thromboembolic prophylaxis, and possibly remdesivir)
Number of subjects: 136
Study 33546739 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 136
Study 33546739 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 136
Study 33046869 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-L1 (durvalumab) plus anti-CTLA-4 (tremelimumab)
Number of subjects: 28
Study 35187678 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Occupational Health Coaching (REOHC)
Number of subjects: 141
Study 35187678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 33963406 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) with explicit financial incentives linked to results
Number of subjects: 0
Study 33963406 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct financing with additional resources available for health providers not linked to performance
Number of subjects: 0
Study 33963406 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced supervision and monitoring without additional resources
Number of subjects: 0
Study 33963406 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36071262 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin as an adjunct to antidepressants
Number of subjects: 0
Study 36071262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32044695 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance specific physiotherapy (Motor Program Activating Therapy in Czech cohort and Sensory-motor Integration Training in Italian cohort)
Number of subjects: 149
Study 32044695 — intervention group
Group type: COMPARATOR
Intervention: Non-balance specific physiotherapy (Vojta reflex locomotion in Czech cohort and conventional dynamic strengthening exercises in Italian cohort)
Number of subjects: 149
Study 32044695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient physiotherapy intensity
Number of subjects: 149
Study 32044695 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of disability
Number of subjects: 149
Study 35114338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion (MM)
Number of subjects: 76
Study 35114338 — intervention group
Group type: COMPARATOR
Intervention: Placebo moxibustion (PM)
Number of subjects: 76
Study 33127554 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 99
Study 33127554 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (CS) injection
Number of subjects: 99
Study 34459702 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab-tiuxetan 0.4 mCi/kg (arm A)
Number of subjects: 146